

#### Neurochemical basis of behavior & Drug therapy of schizophrenia

Dr.Nashwa Abo-Rayah Associate prof. (clinical &experimental pharmacology) Mu'tah University- Faculty of Medicine JORDAN 2024/2025





# **Objectives**

- •1- What is schizophrenia?
- •2- Diagnosis of schizophrenia
- •3- Etiology of schizophrenia
- •4- Pharmacological treatment of shizophrenia
- •5- Mechanism of action of antipsychotic drugs
- •6- Side effects of antipsychotic drugs





Is a serious brain illness which are characterized by severe problems with a person's

- thoughts,
- feelings,
- behavior,
- and use of words and language.

### **Diagnosis of Schizophrenia**

- •Three major clusters of symptoms:
- -Positive
- -Negative
- •Disorganized Functioning in work, relationships, or self-care has
- declined since onset
- •D.D.: <u>addiction</u>, <u>bipolar disorder</u> and <u>depression</u>

 Table 9.1 Summary of the Major Symptom Domains in Schizophrenia

Positive Symptoms	Negative Symptoms	Disorganized Symptoms
Delusions, hallucinations	Avolition, alogia, anhedonia, blunted affect, asociality	Disorganized behavior, disorganized speech

Copyright © John Wiley & Sons, Inc. All rights reserved.

## **Neurochemical basis of Schizophrenia**

### •**Dopamine Theory**

•Schizophrenia is due to: <u>excess levels of dopamine</u>

•Evidence: Drugs that alleviate symptoms reduce dopamine activity

•Amphetamines, which increase dopamine levels, can induce a psychosis

## •Theory explanation:

- <u>Excess numbers</u> of **dopamine receptors** or **oversensitive** dopamine receptors
- Localized mainly in the mesolimbic pathway

•Mesolimbic dopamine abnormalities mainly related to positive symptoms

 Decreased dopamine activity in the mesocortical pathway mainly related to negative symptoms (increased 5HTA activity)

### **Dopaminergic pathway in CNS**



Mesolimbic pathway

Excess activity implicated in:

- Positive symptom schizophrenia

e.g.

- hallucinations
- delusions



Diminished activity implicated in :

- Negative symptoms of schizophrenia e.g.

**Restrictions in** 

- emotion,
- thought,
- speech,
- pleasure and attention.

# **Dopamine theory of schizophrenia**







#### **<u>Atypical</u>** dissociate rapidly from **D**<sub>2</sub> receptor





### **Antipsychotic drugs**

- •**First-generation (typical) antipsychotic medications** (neuroleptics)
- **D** Phenothiazines (chlorpromazine)
- **Butyrophenones** (haloperidol)
- •Mechanism of action: Block dopamine receptors: relieve
- positive symptoms

### •Disadvantages:

- •1- Little effect on negative symptoms
- •2- Extrapyramidal side effects, Neuroleptic malignant syndrome

### **Second-generation** (<u>atypical</u>) antipsychotics

Risperidone , Olanzapine, Clozapine, Quetiapine

•<u>Mechanism of action:</u> Block serotonin receptors and dopamine receptors (loose binding: low risk of both EPS and hyperprolactinemia)

#### •Advantages:

- 1- Fewer motor side effects (extrapyramidal)
- 2- Less noncompliance
- 3- Reduce relapse

#### •<u>Side effects</u>

- 1- Agranulocytosis
- 2- Weight gain

#### Newer medications may improve cognitive function:

- > Olanzapine
- > Risperidone

### Side Effects of Antipsychotic drugs

- •<u>1- Extrapyramidal Symptoms (EPS)</u> •Tremors
- •Dystonia: Involuntary skeletal muscle contractions leading to:
- twisting movements in certain parts of body for a period.
- •**Treatment:** <u>Anticholinergic drugs</u> (e.g. benztropine slow IV) or Antihistaminics (e.g. diphenhydramine)
- •Tardive dyskinesia: repetitive involuntary movements with prolonged use



#### **<u>2- Neuroleptic Malignant Syndrome (NMS): life-threatening</u>** Due to autonomic disturbances

- •Hyperthermia, muscular rigidity, tachycardia, hyper or hypotension,, rhabdomyolysis, confusion
- •Complications: Coma and death

#### •<u>Treatment:</u>

- •Stop drug
- •Supportive management and
- •Sever cases: ICU

#### **3- Autonomic disturbances:**

•Blocking of alpha receptors in blood vessels: postural hypotension

•Sexual dysfunctions: <u>failure of ejaculation</u>: non-compliance (failure of therapy)

•Atropine- like effects

### 4- Endocrinal disturbances: Hyperprolactinemia

Amenorrhea, menstrual cycle disorders, breast enlargement, galactorrhea

- Dose dependent
- Related to D2receptor affinity
- Higher in 1<sup>st</sup> generation as a class

- 5- Polyphagia: <u>Weight Gain and Metabolic Syndrome</u>:
- Due to <u>blocking of 5HT2A</u> receptors in <u>satiety center</u>.
- •More with atypical drugs

### **<u>6- Hematological</u>**

- •Mild leukopenia: common
- •Agranulocytosis and neutropenia infrequent: may be fatal
- •Management: stop the drug
- •Highest risk in clozapine, at beginning of treatment

- •7- CVS:
- •Arrhythmias
- Orthostatic hypotension)
- <u>Antipsychotic drugs with increased risk:</u>
  Haloperidol, olanzapine, risperidone
- •8- Cholestatic jaundice: <u>cholorpromazine</u>

# Summary

	<b>v</b>	
	Typical drugs	Atypical drugs
Members	Chlorpromazine, haloperidol	Risperidone, olanzapine, clozapine
Mechanism of action	Block D2 receptors	Block 5HT2A receptors
Efficacy	Positive symptoms	Negative symptoms
Extrapyramidal symptoms, hyperprolactinemia	+++	+
Neuroleptic malignant syndrome	+++	+
Polyphagia	-	+++
Agranulocytosis	+	+++

#### **References**

Lippincott's Illustrated Review Pharmacology, 8<sup>th</sup> edition

#### Lippincott Williams & Wilkins

**Katzung** by Anthony Trevor, Bertram Katzung, and Susan Masters . 16<sup>th</sup> edition McGraw Hill,

**Rang & Dale's Pharmacology:** by Humphrey P. Rang ; James M. Ritter ; Rod Flower Churchill Livingstone; 10<sup>th</sup> edition



### • Thank you